Similarly, the NLRP3 inflammasome inhibitor glibenclamide also decreases inflammasome activation in human trophoblasts, thus highlighting the therapeutic potential of the NLRP3 inflammasome for the treatment of placental disorders (22). This evidence concerns the gene NLRP3 and placenta disorder.